Skip to main content
. 2023 Jun 28;5(1):vdad078. doi: 10.1093/noajnl/vdad078

Figure 1.

Figure 1.

Unadjusted progression-free survival (PFS) and overall survival (OS) analyses of patients with IDH-wild-type glioblastoma according to TERTp and PTEN status. (A) Unadjusted PFS analysis of patients with and without PTEN loss and/or mutation in IDH- and TERTp-wild-type glioblastomas. (B) Unadjusted OS analysis of patients with and without PTEN loss and/or mutation in IDH- and TERTp-wild-type glioblastomas. (C) Unadjusted PFS analysis of patients with and without PTEN loss and/or mutation in IDH-wild-type and TERTp-mutant glioblastomas. (D) Unadjusted OS analysis of patients with and without PTEN loss and/or mutation in IDH-wild-type and TERTp-mutant glioblastomas.

HHS Vulnerability Disclosure